Interactions of PLA2-s from Vipera lebetina, Vipera berus berus and Naja naja oxiana venom with platelets, bacterial and cancer cells

Toxins

Volumn 5, Issue 2, 2013, Pages 203-223

  Samel, Mari ^a   Vija, Heiki ^a   Kurvet, Imbi ^a   Künnis Beres, Kai ^a   Trummal, Katrin ^a   Subbi, Juhan ^a   Kahru, Anne ^a   Siigur, Jüri ^a  

^a NATIONAL INSTITUTE OF CHEMICAL PHYSICS AND BIOPHYSICS   (Estonia)

Author keywords

Antibacterial; Bioluminescent bacteria; Cancer cells; Human platelet aggregation inhibition; Naja naja oxiana; Phospholipase A2; Snake venom; Vipera berus berus; Vipera lebetina

Indexed keywords

SECRETORY PHOSPHOLIPASE A2; SNAKE VENOM; ANTIINFECTIVE AGENT; CYTOTOXIN; PHOSPHOLIPASE A2; VIPER VENOM;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BACILLUS SUBTILIS; BACTERIAL CELL; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SCREENING; ENZYME PURIFICATION; ESCHERICHIA COLI; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; MOUSE; NAJA NAJA; NAJA NAJA OXIANA; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN INTERACTION; STAPHYLOCOCCUS AUREUS; THROMBOCYTE AGGREGATION; VIBRIO FISCHERI; VIPERA; VIPERA BERUS BERUS; VIPERA LEBETINA; AMINO ACID SEQUENCE; ANIMAL; BACTERIUM; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; ELAPIDAE; ENZYMOLOGY; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; NEOPLASM; SEQUENCE ALIGNMENT; TUMOR CELL LINE; VIPERIDAE;

AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; CELL LINE, TUMOR; CELL SURVIVAL; CYTOTOXINS; ELAPID VENOMS; ELAPIDAE; HUMANS; MICE; MOLECULAR SEQUENCE DATA; NEOPLASMS; PHOSPHOLIPASES A2; PLATELET AGGREGATION; SEQUENCE ALIGNMENT; VIPER VENOMS; VIPERIDAE;

MLCS; MLOWN;

EID: 84873551946     PISSN: 20726651     EISSN: None     Source Type: Journal    
DOI: 10.3390/toxins5020203     Document Type: Article

References (71)

1. Murakami, M.; Taketomi, Y.; Miki, Y.; Sato, H.; Hirabayashi, T.; Yamamoto, K. Recent progress in phospholipase A2 research: From cells to animals to humans. Progr. Lipid Res. 2011, 50, 152-192.
2. 2 superfamily and its group numbering system. Biochim. Biophys. Acta 2006, 1761, 1246-1259.
3. 2 structure/function, mechanism, and signaling. J. Lipid Res. 2009, 59, S237-S242.
4. Nevalainen, T.J.; Cardoso, J.C.; Riikonen, P.T. Conserved domains and evolution of secreted phospholipases A(2). FEBS J. 2012, 279, 636-649.
5. 2 venoms: Biological activities and their possible adaptive roles. Protein Pept. Lett. 2009, 16, 860-876.
6. 2 Enzymes. In Handbook of Venoms and Toxins of Reptiles; Mackessy, S.P., Ed.; CRC Press: Boca Raton, FL, USA, 2010; pp. 173-205.
7. 2 enzymes. Toxicon 2003, 42, 827-840.
8. 2 enzymes from snake venoms. Toxicon 2005, 45, 1147-1161.
9. 2. Trends Pharmacol. Sci. 1999, 20, 162-170.
10. 2 from snake venoms: Effects on catalytic and pharmacological properties Toxicon 2003, 42, 855-868.
11. 2 myotoxins and neurotoxins: Common aspects of their mechanism of action. Cell. Mol. Life Sci. 2008, 65, 2897-2912.
12. 2: A new class of antitumor agents. Protein Pept. Lett. 2009, 16, 894-898.
13. Ouyang, C.; Huang, T.F. Potent platelet aggregation inhibitor from Trimeresurus gramineus snake venom. Biochim. Biophys. Acta 1983, 757, 332-341.
14. 2 from the venom of Agkistrodon acutus (five pace snake) and its effect on platelet aggregation. Toxicon 1989, 27, 675-682.
15. 2 Rnzymes: Dtructure, Gunction and Mechanism; Kini, R.M., Ed.; John Wiley & Sons: Chichester, UK, 1997; pp. 369-387.
16. Sim, K.L. Purification and preliminary characterisation of praelongin phospholipases, antiplatelet agents from the snake venom of Acanthophis praelongus. Biochim. Biophys. Acta 1998, 1379, 198-206.
17. 2 isolated from Bothrops jararacussu snake venom. Biochimie 2004, 86, 731-739.
18. 2 from the snake venom of Vipera lebetina (Levantine viper). Toxicon 2009, 54, 429-439.
19. 2 and a Kunitz-type protease inhibitor from steppe viper Vipera ursinii renardi. Toxicon 2011, 57, 332-341.
20. 2 from Russell's viper (Vipera russelli) venom: Isolation and characterization. Toxicon 1996, 34, 1173-1185.
21. 2 isolated from Lachesis muta (Bushmaster) snake venom. Thromb. Haemost. 1997, 78, 1372-1380.
22. Chow, G.; Subburaju, S.; Kini, R.M. Purification, characterization, and amino acid sequence determination of acanthins, potent inhibitors of platelet aggregation from Acanthophis antarcticus (common death adder) venom. Arch. Biochem. Biophys. 1998, 354, 232-238.
23. 2 from Indian saw-scaled viper (Echis carinatus) venom. Toxicon 1999, 37, 1659-1671.
24. 2, from the venom of the snake Bothrops jararaca: Purification, primary structure analysis, and its characterization as a platelet-aggregation-inhibiting factor. Arch. Biochem. Biophys. 1999, 367, 26-32.
25. 2 from Bothrops jararacussu venom. Protein J. 2004, 23, 273-285.
26. 2 from Indian cobra (Naja Naja) venom. Biochimie 2004, 86, 203-210.
27. Páramo, L.; Lomonte, B.; Pizarro-Cerdá, J.; Bengoechea, J.A.; Gorvel, J.P.; Moreno, E. Bactericidal activity of Lys49 and Asp49 myotoxic phospholipases A2 from Bothrops asper snake venom-Synthetic Lys49 myotoxin II-(115-129)-peptide identifies its bactericidal region. Eur. J. Biochem. 1998, 253, 452-461.
28. 2. J. Biol. Chem. 2002, 277, 5849-5857.
29. 2 isolated from Crotalus durissus terrificus venom. J. Protein Chem. 2002, 21, 161-168.
30. 2 homologue from the venom of the snake Bothrops atrox. Toxicon 2004, 44, 91-101.
31. 2 from Bothrops neuwiedi pauloensis snake venom. Toxicon 2004, 44, 305-314.
32. 2 from crotalid snake venoms and synthetic peptide variants derived from their C-terminal region. Toxicon 2005, 45, 807-815.
33. 2 from Bungarus fasciatus venom. Peptides 2007, 28, 969-973.
34. 2 from the venom of Agkistrodon halys (Chinese pallas). Biochimie 2008, 90, 1372-1388.
35. 2 from the venom of the Saw-scaled viper: Novel bactericidal and membrane damaging activities. Biochimie 2010, 92, 1854-1866.
36. 2 and L-amino acid oxidase. Toxicon 2010, 55, 795-804.
37. Samy, R.P.; Stiles, B.G.; Gopalakrishnakone, P.; Chow, V.T. Antimicrobial proteins from snake venoms: Direct bacterial damage and activation of innate immunity against Staphylococcus aureus skin infection. Curr. Med. Chem. 2011, 18, 5104-5113.
38. 2 from the Crotalus durissus collilineatus venom. Protein J. 2005, 24, 103-112.
39. Nevalainen, T.J.; Graham, G.G.; Scott, K.F. Antibacterial actions of secreted phospholipases A2. Biochim. Biophys. Acta 2008, 1781, 1-9.
40. 2 cDNA from Bothrops jararacussu venom gland. Protein Expr. Purif. 2004, 37, 102-108.
41. 2 from Russell's viper venom. J. Chromatogr. B 2007, 845, 232-243.
42. 2 from Cerastes cerastes venom, that inhibit cancerous cell adhesion and migration. Toxicon 2009, 53, 444-453.
43. Chen, K.C.; Liu, W.H.; Chang, L.S. Taiwan cobra phospholipase A2-elicited JNK activation is responsible for autocrine fas-mediated cell death and modulating Bcl-2 and Bax protein expression in human leukemia K562 cells. J. Cell Biochem. 2010, 109, 245-254.
44. 2 from Protobothrops flavoviridis venom induces caspase-independent apoptotic cell death accompanied by rapid plasma-membrane rupture in human leukemia cells. Biosci. Biotechnol. Biochem. 2011, 75, 864-870.
45. Khunsap, S.; Pakmanee, N.; Khow, O.; Chanhome, L.; Sitprija, V.; Suntravat, M.; Lucena, S.E.; Perez, J.C.; Sánchez, E.E.J. Purification of a phospholipase A(2) from Daboia russelii siamensis venom with anticancer effects. Venom Res. 2011, 2, 42-51.
46. 2 from Macrovipera lebetina transmediterranea venom, inhibits tumor cells adhesion and migration. Matrix Biol. 2009, 28, 188-193.
47. 2, inhibits angiogenesis through an increase in microtubule dynamics and disorganization of focal adhesions. PLoS One 2010, 5, e10124.
48. 2 from the venom of the common viper, Vipera berus berus. Biochim. Biophys. Acta 1993, 1157, 81-85.
49. 2 (isozyme E3) from the venom of middle Asian cobra Naja naja oxiana. J. Bioorg. Khim. 1979, 5, 805-813.
50. Kahru, A. In vitro toxicity testing using marine luminescent bacteria Photobacterium phosphoreum: The BiotoxTM test. Atla-Altern. Lab. Anim. 1993, 21, 210-215.
51. 2. Blood 1995, 86, 4166-4174.
52. 2 isoenzyme isolated from Lachesis muta snake venom. Biochem. Pharmacol. 2002, 63, 1589-1597.
53. 2 MiPLA-1, from micropechis ikeheka venom. Arch. Biochem. Biophys. 1999, 369, 181-192.
54. Barbosa, P.S.; Martins, A.M.; Havt, A.; Toyama, D.O.; Evangelista, J.S.; Ferreira, D.P.; Joazeiro, P.P.; Beriam, L.O.; Toyama, M.H.; Fonteles, M.C.; Monteiro, H.S. Renal and antibacterial effects induced by myotoxin I and II isolated from Bothrops jararacussu venom. Toxicon 2005, 46, 376-386.
55. Costa, T.R.; Menaldo, D.L.; Oliveira, C.Z.; Santos-Filho, N.A.; Teixeira, S.S.; Nomizo, A.; Fuly, A.L.; Monteiro, M.C.; de Souza, B.M.; Palma, M.S.; et al. Myotoxic phospholipases A(2) isolated from Bothrops brazili snake venom and synthetic peptides derived from their C-terminal region: Cytotoxic effect on microorganism and tumor cells. Peptides 2008, 29, 1645-1656.
56. Glukhov, E.; Stark, M.; Burrows, L.L.; Deber, C.M. Basis for selectivity of cationic antimicrobial peptides for bacterial versus mammalian membranes. J. Biol. Chem. 2005, 280, 33960-33967.
57. 2 as targets for anti-cancer drugs. Biochem. Pharmacol. 2007, 74, 949-959.
58. Yan, C.H.; Liang, Z.Q.; Gu, Z.L.; Yang, Y.P.; Reid, P.; Qin, Z.H. Contributions of autophagic and apoptotic mechanisms to CrTX-induced death of K562 cells. Toxicon 2006, 47, 521-530.
59. Yan, C.H.; Yang, Y.P.; Qin, Z.H.; Gu, Z.L.; Reid, P.; Liang, Z.Q. Autophagy is involved in cytotoxic effects of crotoxin in human breast cancer cell line MCF-7 cells. Acta Pharmacol. Sin. 2007, 28, 540-548.
60. Ye, B.; Xie, Y.; Qin, Z.H.; Wu, J.C.; Han, R.; He, J.K. Anti-tumor activity of CrTX in human lung adenocarcinoma cell line A549. Acta Pharmacol. Sin. 2011, 32, 1397-1401.
61. 2 NSC-624 244) in patients with advanced cancer. Clin. Cancer Res. 2002, 8, 1033-1041.
62. 2 from Bothrops leucurus venom (white-tailed-jararaca) snake venom. Biochimie 2007, 89, 319-328.
63. 2 and apoptosis. Biochim. Biophys. Acta 2002, 1585, 72-76.
64. Sved, P.; Scott, K.F.; McLeod, D.; King, N.J.; Singh, J.; Tsatralis, T.; Nikolov, B.; Boulas, J.; Nallan, L.; Gelb, M.H.; et al. Oncogenic action of secreted phospholipase A2 in prostate cancer. Cancer Res. 2004, 64, 6934-6940.
65. De Haas, G.H.; Postema, N.M.; Nieuwenhuizen, W.; van Deenen, L.L.M. Purification and properties of phospholipase A from porcine pancreas. Biochim. Biophys. Acta 1968, 159, 103-117.
66. Laemmli, U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227, 680-685.
67. Vesterberg, O. Isoelectric focusing of proteins in polyacrylamide gels. Biochim. Biophys. Acta 1972, 257, 11-19.
68. Siigur, E.; Aaspõllu, A.; Trummal, K.; Tõnismägi, K.; Tammiste, I.; Kalkkinen, N.; Siigur, J. Factor X activator from Vipera lebetina venom is synthesized from different genes. Biochim. Biophys. Acta 2004, 1702, 41-51.
69. Siigur, J.; Samel, M.; Tõnismägi, K.; Subbi, J.; Siigur, E.; Tu, A.T. Biochemical characterization of lebetase, a direct-acting fibrinolytic enzyme from Vipera lebetina snake venom. Thromb. Res. 1998, 90, 39-49.
70. Ivask, A.; Rõlova, T.; Kahru, A. A suite of recombinant luminescent bacterial strains for the quantification of bioavailable heavy metals and toxicity testing. BMC Biotechnol. 2009, 9, 41.
71. Kurvet, I.; Ivask, A.; Bondarenko, O.; Sihtmäe, M.; Kahru, A. LuxCDABE-Transformed Constitutively Bioluminescent Escherichia coli for toxicity Screening: Comparison with naturally luminous Vibrio fischeri. Sensors 2011, 11, 7865-7878.